In this study, we extend this understanding by validating the antitumor activity of our in-house made hERG activators in breast cancer cells and further exploring the mechanisms underlying their anti-proliferative, anti-migratory and anti-invasive effects. The gene discussed is KCNH2; the disease is breast carcinoma.